All In Biotech

Investigational drug · Phase 2

EDG-15400

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Heart Failure With Preserved Ejection Fraction.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "EDG-15400"

First trial start

2026

Aug 25, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "EDG-15400", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Heart Failure With Preserved Ejection Fraction

Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "EDG-15400" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Heart Failure With Preserved Ejection Fraction

  • Maridebart cafraglutideAMG 133Phase 314 trials

    Amgen · Obesity, Overweight, Obstructive Sleep Apnea

  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • HRS-1893Phase 35 trials

    Shandong Suncadia Medicine Co., Ltd. · Obstructive Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy

  • HS235Phase 22 trials

    35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

  • TX000045Phase 22 trials

    Tectonic Therapeutic · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction, Hypertension, Pulmonary

  • JK07Phase 21 trial

    Salubris Biotherapeutics Inc · Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.